Therapeutics News and Research

RSS

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

New method for detecting breast cancer at 'stage 0'

RNL Natural Co., Ltd, a leading biotech company specialized in adult stem cell therapeutics affiliated with RNL BIO Co., Ltd., introduced on June 22, 2011 a new method of detecting breast cancer as early as at 'stage 0' through breath VOCs.

25 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Combination of strategies reduces more than half the number of tiger mosquitos

The combination of three complementary measures to eradicate tiger mosquitos - avoid having stagnant water, using insecticides to eliminate larvae and adults, and removing rubbish - reduces more than half the number of tiger mosquitos, according to a research coordinated by researchers at Universitat Autonoma de Barcelona.

22 Jul 2011

A*STAR's ETC, Agilent introduce drug screening platform

Agilent Technologies Inc. and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre.

22 Jul 2011

Scripps Research, Jupiter Medical Center partner for cancer study

In a first for both institutions, Jupiter Medical Center, the area's Number One Preferred Hospital, and The Scripps Research Institute, one of the world's largest private, non-profit biomedical research organizations, are teaming up to conduct research on human cancer tissue.

22 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Promising compounds for new anti-obesity drugs

Though it generally is known that obesity dramatically increases the risk for type 2 diabetes, the biological mechanisms for that connection still are unclear.

21 Jul 2011

Researchers identify IDOL protein as potential new target for lowering LDL cholesterol

High levels of 'bad' cholesterol (LDL cholesterol) are a risk factor for developing atherosclerotic cardiovascular disease (ASCVD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke.

21 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

PrioNet Canada awards University of Western Ontario $600,000 to study neurodegenerative disorders

The University of Western Ontario is one of nine universities which will share 2.9 million dollars in research grants announced by PrioNet Canada to study Prion diseases and neurodegenerative disorders including Alzheimer's.

21 Jul 2011

USPTO issues patent for Mirna's tumor suppressor microRNAs

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed multiple patent claims related to the therapeutic application of several tumor suppressor microRNAs.

21 Jul 2011

SuperGen closes acquisition of Astex

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction to acquire Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies.

21 Jul 2011

USPTO issues patent for Avila's targeted covalent drugs portfolio

Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."

21 Jul 2011

Registration now open for Transcatheter Cardiovascular Therapeutics 2011

Registration is now open for TCT 2011(Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation, which will return to San Francisco, California, November 7-11, 2011.

20 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Therapeutics News and Research

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

New method for detecting breast cancer at 'stage 0'

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Combination of strategies reduces more than half the number of tiger mosquitos

A*STAR's ETC, Agilent introduce drug screening platform

Scripps Research, Jupiter Medical Center partner for cancer study

Australian anti-cancer company completes $2.6 million placement

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Baxter net income increases 15% to $615 million for second quarter 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Promising compounds for new anti-obesity drugs

Researchers identify IDOL protein as potential new target for lowering LDL cholesterol

AMAG enters definitive merger agreement with Allos Therapeutics

PrioNet Canada awards University of Western Ontario $600,000 to study neurodegenerative disorders

USPTO issues patent for Mirna's tumor suppressor microRNAs

SuperGen closes acquisition of Astex

USPTO issues patent for Avila's targeted covalent drugs portfolio

Registration now open for Transcatheter Cardiovascular Therapeutics 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News